Dengue vaccine a step closer? India's first phase 3 trial hits 50% enrolment mark, early data shows no safety concerns
Developed by Panacea Biotec Limited under a licensing agreement with the National Institutes of Health (NIH), the primary US federal agency for biomedical research, DengiAll targets all four dengue virus subtypes and has shown promising results in earlier clinical trials.
What is the dengue vaccine DengiAll about?
DengiAll has a weakened form of all four dengue virus subtypes and has the same virus composition as the vaccine developed by NIH, except for the inactive ingredients. The NIH also evaluated the vaccine in the US and the results were found to be promising in the early-stage clinical studies. A Phase I and II clinical trial conducted in India revealed a balanced and robust immune response across all four dengue virus types. The vaccine was also found to be safe and well-tolerated.
Multiple ICMR institutes are involved in the study to evaluate the efficacy, immunogenicity and safety of DengiAll. The ICMR-National Institute of Translational Virology (NITVAR) and AIDS Research (formerly ICMR-NARI) is responsible for overall trial coordination.
Dr Sheela Godbole, director, ICMR-NITVAR and national principal investigator of the trial, told The Indian Express that the follow-up will be completed in the last quarter of 2027.
According to Dr Abhijit Kadam, national co-principal investigator, healthy adults in the 18-60 year age group are being screened and randomised to receive either the dengue vaccine or a placebo (2:1). 'They will be followed up for two years,' he said.
Dr Suchit Kamble, principal investigator for the NITVAR clinical trial site, explains that the vaccine would help in prevention of a disease that has no treatment. 'Some of the infections could result in severe manifestations like bleeding and sudden drop in blood flow and may threaten the life of the patient,' he said.
The 20 trial sites are located in the following cities: Chennai, Pune (with two sites), Mysuru, Hyderabad, Puducherry, Kochi, Jodhpur, Ranchi, Kolkata, Aligarh, Patna, Rohtak, Ludhiana, Bengaluru, New Delhi, Bhubaneswar, Rishikesh, Guwahati, and Faridabad. The research teams at these sites come from well-known medical institutions, including three affiliated with ICMR.
Dengue fever is one of the top 10 threats to global health, according to the World Health Organisation (WHO). India accounts for a large fraction of global dengue cases and the disease is endemic (regularly occurring within an area or community) in certain regions.
Data from the National Centre for Vector Borne Diseases Control, Ministry of Health and Family Welfare, shows that till March this year, around 12,043 dengue cases were reported, while 2.3 lakh cases and 297 deaths were reported in 2024.
Anuradha Mascarenhas is a journalist with The Indian Express and is based in Pune. A senior editor, Anuradha writes on health, research developments in the field of science and environment and takes keen interest in covering women's issues. With a career spanning over 25 years, Anuradha has also led teams and often coordinated the edition.
... Read More
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
an hour ago
- NDTV
CRISPR Explained: How Gene Editing Is Reshaping Medicine
CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool originally discovered as a bacterial defence mechanism. Scientists have repurposed it to make highly accurate cuts in DNA using a Cas nuclease enzyme paired with a programmable guide RNA. This allows precise editing at any point in the genome. According to the National Institutes of Health (NIH), CRISPR/Cas9 is transforming biomedical research by enabling scientists to correct genetic errors and regulate genes in cells and organisms quickly, affordably, and with remarkable precision. Its simplicity, efficiency, and wide applicability are reshaping how medicine approaches genetic disorders, cancer, and rare diseases. Since 2019, CRISPR therapies have moved from concept to clinic. The first patient, Victoria Grey, received CRISPR treatment for sickle cell disease (SCD), resulting in a cure that eliminated her pain crises, according to NPR. Then, in December 2023, the FDA approved Casgevy (exagamglogene autotemcel)-the world's first CRISPR-based therapy for SCD and beta-thalassemia, using edited haematopoietic stem cells to reactivate foetal haemoglobin, according to Harvard Medical School. Clinical advances haven't stopped there. Innovative lipid nanoparticle (LNP) systems, used by Intellia and others, are showing early success in in vivo gene editing targeting liver and other tissues, according to CRISPR Medicine News. A landmark case this spring involved a six-month-old with CPS1 deficiency treated with personalised CRISPR base editing using LNPs, dramatically improving his condition without a transplant, according to The Sun. However, challenges remain. Off-target edits are a concern, though machine-learning models aim to predict and reduce these events. Additionally, delivery systems and scaling up for complex diseases continue to be refined, according to Journal Nature. Today, CRISPR is the most accessible and versatile gene-editing tool, vastly outpacing earlier systems thanks to its RNA-guided simplicity. As delivery improves and immunogenicity is managed, CRISPR's potential is expanding from curing rare genetic disorders to treating cancers, metabolic diseases, and possibly even trisomy-21 via chromosome-specific editing. In summary, CRISPR has already reshaped modern medicine: achieving historic cures in haematology, pioneering in vivo editing, and spearheading personalised therapies. As precision, safety, and delivery innovation accelerate, CRISPR-driven treatments promise to redefine patient care for decades to come.
News18
5 hours ago
- News18
The Best Time And Method To Naturally Boost Your Vitamin D, Backed By Science
Approximately 1 billion people are suffering from Vitamin D deficiency, according to the National Library of Medicine in the United States. From strengthening your bone health to boosting your immunity, Vitamin D is an essential nutrient for your body to function at its optimum levels. Known as the sunshine vitamin, Vitamin D is also critical for mood regulation. A fat-soluble nutrient, this vitamin exists in two forms. Vitamin D2 (ergocalciferol), which is derived from plant-based sources and fortified foods, and Vitamin D3 (cholecalciferol) raised through essential sunlight exposure and also animal-based food intake. According to the National Institutes of Health (NIH) in the United States, your body requires about 400–800 International Units (IU), or 10–20 micrograms (mcg) of Vitamin D to maintain its healthy state. The Vitamin D consumption inside your body also depends on multiple factors, including your age, skin colour, current blood vitamin D levels and sun exposure. Approximately 1 billion people across the globe are suffering from Vitamin D deficiency, according to the USA's National Library of Medicine. In certain countries, the rate of Vitamin D-deficient population stretches up to 50%. In a busy world, improper diets, irregular sun exposure and several diseases have led to such a scenario. Most Effective Way To Boost Vitamin D Levels If you're dealing with Vitamin D deficiency, regular sunlight exposure is the way to go. It is the most effective way to inhale the fat-soluble nutrient that provides wider benefits to your body. When our skin is exposed to sunlight, it naturally generates Vitamin D from cholesterol. The Vitamin D synthesis process begins when the cholesterol in your skin cells meets ultraviolet B (UVB) rays, making sustained production of the essential nutrient. Since UV rays are most intense during the afternoon, midday is considered the best time to get your sun exposure while ensuring you avoid sunburn. There are also dietary sources to get the Vitamin D flow going inside your body. Non-vegetarian dietary options to raise the nutrient intake include fatty fish (salmon, mackerel), and egg yolks, while those who are vegetarian can opt for milk and orange juice. If your lifestyle makes it difficult to consume Vitamin D through both sun exposure and food options, a healthcare professional would recommend supplements. However, taking these supplements increases the risk of overdosing. The Vitamin D overdose can also be harmful, causing toxicity, nausea or kidney problems. First Published: July 05, 2025, 11:35 IST
India Gazette
a day ago
- India Gazette
Nipah virus alert issued in three Kerala districts after two suspected cases
Thiruvananthapuram (Kerala) [India], July 4 (ANI): Health authorities in Kerala have issued an alert in three districts -- Kozhikode, Malappuram and Palakkad after two suspected cases of the Nipah virus were detected. Kerala Health Minister Veena George said that the suspected cases of Nipah virus are from Palakkad and Malappuram districts. 'An alert has been issued in three districts of Kerala, namely Kozhikode, Malappuram and Palakkad, in connection with two new Nipah virus cases,' she said. The tests conducted at medical college hospitals in Malappuram and Kozhikode have confirmed the infections. Samples have also been sent to the National Institute of Virology (NIV) in Pune for further confirmation. Even as a final confirmation is awaited, the government has directed officials to strengthen preventive measures to contain the spread of the virus. The Health Minister said that 26 committees have been formed across districts to coordinate the response. Police support will be sought to prepare a contact list, and state and district-level helplines will be activated. District Collectors have been directed to make arrangements for declaring containment zones if required. The National Institute of Virology (NIV), Pune, is the only lab in the country that cultures the Nipah virus. The virus, which is zoonotic in nature (transmitted from animals to humans), can also spread through contaminated food or directly between people. The symptoms of the Nipah virus are fever, headaches, muscle pain, vomiting, sore throat, dizziness, altered consciousness, and Atypical pneumonia. In infected people, it causes a range of illnesses from asymptomatic (subclinical) infection to acute respiratory illness and fatal encephalitis. Nipah Virus Disease (NiVD) has a mortality rate of 50 per cent, making it one of the most dangerous viral diseases. The Indian Council of Medical Research (ICMR) developed RAMBAAN, a Mobile BSL-3 [MBSL-3] laboratory, an innovative initiative for providing the diagnostic surge capacity for enhancing the onsite laboratory services during the outbreaks of known and unknown high-risk pathogens. RAMBAAN, a Made-in-India rapid action mobile lab, was also deployed in response to the Nipah virus outbreak in Kerala in 2023 and 2024. 'The MBSL-3 was successfully deployed and operationalised for the first time in response to the Nipah virus (NiV) outbreak in Kozhikode, Kerala, India, in September 2023 and again in Malappuram District of Kerala state in July 2024,' said ICMR. This 'laboratory on wheels' represents a significant advancement in outbreak investigation and public health emergency response in India. The ICMR is also working on an indigenous vaccine for the Nipah virus. (ANI)
